• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Aurora Cannabis Inc.

    6/1/22 10:14:29 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ACB alert in real time by email
    SC 13G 1 tm2217396d1_sc13g.htm SC 13G

     

    CUSIP No: 05156X884

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. ____)*

     

    Aurora Cannabis Inc.

    (Name of Issuer)

     

    Common Shares, no par value

    (Title of Class of Securities)

     

    05156X884

    (CUSIP Number)

     

    May 27, 2022

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨  Rule 13d-1(b)

    x Rule 13d-1(c)

    ¨  Rule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No: 05156X884

     

    (1)  NAMES OF REPORTING PERSONS
     
      CVI Investments, Inc.
     
    (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)    ¨
        (b)    ¨
     
    (3)  SEC USE ONLY
     
    (4)  CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Cayman Islands
       

      (5) SOLE VOTING POWER
     
      0
     
    NUMBER OF (6) SHARED VOTING POWER **
    SHARES
    BENEFICIALLY 16,500,000
    OWNED BY
    EACH (7) SOLE DISPOSITIVE POWER
    REPORTING    
    PERSON WITH 0
     
      (8) SHARED DISPOSITIVE POWER **
     
      16,500,000

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      16,500,000
     
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
        ¨
     
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     
      5.7%
     
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 05156X884

     

    (1)  NAMES OF REPORTING PERSONS
     
     

    Heights Capital Management, Inc.

     
    (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)    ¨
        (b)    ¨
     
    (3)  SEC USE ONLY
     
    (4)  CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Delaware
       

      (5) SOLE VOTING POWER
     
      0
     
    NUMBER OF (6) SHARED VOTING POWER **
    SHARES
    BENEFICIALLY 16,500,000
    OWNED BY
    EACH (7) SOLE DISPOSITIVE POWER
    REPORTING    
    PERSON WITH 0
     
      (8) SHARED DISPOSITIVE POWER **
     
      16,500,000

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      16,500,000
     
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
        ¨
     
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     
      5.7%
     
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 05156X884

     

    Item 1. 

     

    (a)      Name of Issuer

     

    Aurora Cannabis Inc. (the “Company”)

     

    (b)     Address of Issuer’s Principal Executive Offices

     

    4818 31 Street East, Edmonton International Airport, Alberta, Canada T9E 4N7

     

    Item 2(a).       Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the common shares of the Company, no par value (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b).       Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c).       Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)        Title of Class of Securities

     

    Common shares, no par value

     

    Item 2(e)        CUSIP Number

     

    05156X884

     

     

     

     

    CUSIP No: 05156X884

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)   ¨   A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4.            Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The Company’s Prospectus Supplement (to Short Form Base Shelf Prospectus dated March 29, 2021, Registration No. 333-254096), filed on May 31, 2022, indicates there were 288,571,576 Shares outstanding (excluding Shares underlying warrants issued at the same time) as of the completion of the offering of the Shares referred to therein.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5.            Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

     

     

     

    CUSIP No: 05156X884

     

    Item 6.            Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.            Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8.            Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.            Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.          Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 05156X884

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: June 1, 2022

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
           
    By: Heights Capital Management, Inc. pursuant to a Limited   By: /s/ Brian Sopinsky
    Power of Attorney, a copy of which is attached as Exhibit I hereto   Name:     Brian Sopinsky
        Title:         Secretary
    By: /s/ Brian Sopinsky      
    Name:    Brian Sopinsky      
    Title:         Secretary      

     

     

     

     

    CUSIP No: 05156X884

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney
    II   Joint Filing Agreement

     

     

     

     

    CUSIP No: 05156X884

     

    Exhibit I

     

    LIMITED POWER OF ATTORNEY

     

    THIS LIMITED POWER OF ATTORNEY given on the 16th day of July, 2015 by CVI Investments, Inc. (hereinafter called "the Company"), whose Registered Office is situated at PO Box 309GT, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands.

     

    WHEREAS, by agreement dated July 16, 2015, by and between the Company and Heights Capital Management, Inc., the Company expressly authorized Heights Capital Management, Inc. to enter into transactions in certain designated areas as defined in the Discretionary Investment Management Agreement attached hereto marked "Appendix l."

     

    NOW THIS DEED WITNESSETH that William Walmsley, Director of the Company, hereby appoints on behalf of the Company the firm of HEIGHTS CAPITAL MANAGEMENT, INC., which through its officers, directors and employees is hereby formally granted limited power of attorney for the purpose of entering into transactions on behalf and for the account of the Company; and to take all actions on behalf of the Company as may be necessary to consummate such transactions, including but not limited to making, negotiating; signing, endorsing, executing, acknowledging and delivering in the name of the Company all applications, contracts, agreements, notes, statements, certificates, proxies and any other instruments of whatever kind and nature as may be necessary or proper in connection with the entering into of such transactions, instructing the transfer of funds where necessary with respect to such transactions, and performing all of the services specified under the Discretionary Investment Management Agreement with respect to such transactions.

     

    IN WITNESS WHEREOF, the Company has caused this Limited Power of Attorney to take effect on the day and year above written.

     

      CVI Investments, Inc.
     
      By: /s/ William Walmsley
               William Walmsley, Director

     

     

     

     

    CUSIP No: 05156X884

     

    EXHIBIT II

     

    JOINT FILING AGREEMENT

     

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the common shares of Aurora Cannabis Inc., no par value, is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

     

    Dated as of June 1, 2022

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
           
    By: Heights Capital Management, Inc. pursuant to a Limited   By: /s/ Brian Sopinsky
    Power of Attorney,   Name:     Brian Sopinsky
        Title:         Secretary
    By: /s/ Brian Sopinsky      
    Name:    Brian Sopinsky      
    Title:         Secretary      

     

     

     

    Get the next $ACB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACB

    DatePrice TargetRatingAnalyst
    12/11/2024Buy
    TD Cowen
    2/9/2024Hold → Buy
    Canaccord Genuity
    9/21/2022Sell → Hold
    Canaccord Genuity
    6/24/2022Neutral → Overweight
    Cantor Fitzgerald
    6/6/2022Sell → Hold
    Stifel
    11/10/2021$9.60 → $10.75Neutral
    Cantor Fitzgerald
    10/28/2021$9.50 → $9.60Neutral
    Cantor Fitzgerald
    10/5/2021$8.30 → $9.50Neutral
    Cantor Fitzgerald
    More analyst ratings

    $ACB
    SEC Filings

    See more
    • SEC Form 6-K filed by Aurora Cannabis Inc.

      6-K - AURORA CANNABIS INC (0001683541) (Filer)

      6/4/25 10:31:15 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Aurora Cannabis Inc.

      6-K - AURORA CANNABIS INC (0001683541) (Filer)

      5/27/25 6:49:58 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Aurora Cannabis Inc.

      6-K - AURORA CANNABIS INC (0001683541) (Filer)

      3/20/25 9:27:09 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aurora Expands Medical Cannabis Offerings in Australia with the Launch of IndiMed TEMPO 22

      NASDAQ | TSX: ACB  Canada's Largest Medical Cannabis Company Adds Two New Cultivars to Popular Brand Portfolio in the Australian Market EDMONTON, AB, June 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, has expanded their popular IndiMed brand with the launch of IndiMed TEMPO 22, available through the company's subsidiary, MedReleaf Australia. With the same consistent quality and reliable supply, this new 22% THC potency creates a greater range of treatment options available to prescribers. "Expanding our portfolio in the value segment in Australia reinforces our commitment to meet increasingly diversified pati

      6/5/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2025 Investor Conference Call and File Related Year End Information

      NASDAQ | TSX: ACB EDMONTON, AB, June 3, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2025 on Wednesday, June 18, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter fiscal year 2025 before the opening of markets that same day. Conference Call Details DATE: Wednesday, June 18, 2025

      6/3/25 4:15:00 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora to Participate in TD Cowen's 9th Annual Future of the Consumer Conference

      NASDAQ | TSX: ACB Canada's Largest Medical Cannabis Company to Discuss Key Trends, Market Opportunities and the Future of the Global Cannabis Industry EDMONTON, AB, May 27, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, will participate in TD Cowen's 9th Annual Future of the Consumer Conference in New York City, NY. Simona King, Chief Financial Officer at Aurora, will take part in a fireside chat and one-on-one meetings with investors on June 3, 2025, at 2:45pm EST. Conference Call Details DATE: Tues

      5/27/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Aurora Cannabis

      TD Cowen initiated coverage of Aurora Cannabis with a rating of Buy

      12/11/24 10:35:16 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis upgraded by Canaccord Genuity

      Canaccord Genuity upgraded Aurora Cannabis from Hold to Buy

      2/9/24 6:09:16 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis upgraded by Canaccord Genuity

      Canaccord Genuity upgraded Aurora Cannabis from Sell to Hold

      9/21/22 9:02:55 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    Financials

    Live finance-specific insights

    See more
    • Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2025 Investor Conference Call and File Related Year End Information

      NASDAQ | TSX: ACB EDMONTON, AB, June 3, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2025 on Wednesday, June 18, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter fiscal year 2025 before the opening of markets that same day. Conference Call Details DATE: Wednesday, June 18, 2025

      6/3/25 4:15:00 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora to Participate in TD Cowen's 9th Annual Future of the Consumer Conference

      NASDAQ | TSX: ACB Canada's Largest Medical Cannabis Company to Discuss Key Trends, Market Opportunities and the Future of the Global Cannabis Industry EDMONTON, AB, May 27, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, will participate in TD Cowen's 9th Annual Future of the Consumer Conference in New York City, NY. Simona King, Chief Financial Officer at Aurora, will take part in a fireside chat and one-on-one meetings with investors on June 3, 2025, at 2:45pm EST. Conference Call Details DATE: Tues

      5/27/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis Announces Fiscal 2025 Third Quarter Results

      NASDAQ | TSX: ACB Reports Total Net Revenue1 of $88.2 Million, up 37% YoY, Including Record Net Revenue1 of $68.1 Million in Global Medical Cannabis, up 51% YoYGenerates Record Net Income of $31.2 Million, up 282% YoY, and Record Adjusted EBITDA1 of $23.1 Million, up 316% YoYAchieves Target of Positive Free Cash Flow1 in Q3, Generating $27.4 Million of Free Cash Flow1Maintains Strong Balance Sheet with $180 Million of Cash and Debt-Free Cannabis Business2EDMONTON, AB, Feb. 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third qu

      2/5/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

      SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

      2/14/23 11:28:04 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Aurora Cannabis Inc.

      SC 13G - AURORA CANNABIS INC (0001683541) (Subject)

      6/1/22 10:14:29 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

      SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

      2/14/22 3:54:29 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    Leadership Updates

    Live Leadership Updates

    See more
    • Rubicon Organics Announces Appointment of Glen Ibbott as Interim CFO

      VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) ("Rubicon Organics" or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX:ACB, NASDAQ:ACB) as its Interim Chief Financial Officer. Janis Risbin, current CFO, will be stepping away from her full-time role effective today. She will remain in an advisory role over the next few months to ensure a smooth transition of responsibilities to Mr. Ibbott. "Glen's leadership at Aurora C

      5/15/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora CEO Miguel Martin takes on additional role as Executive Chairman of Board of Directors

      NASDAQ | TSX: ACB Outgoing Chairman Ron Funk appointed Lead Independent Director, as part of Board leadership transition EDMONTON, AB, Sept. 20, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced the appointments of CEO Miguel Martin to the additional role of Executive Chairman and outgoing Chairman Ron Funk as Lead Independent Director. Both appointments follow unanimous votes by Aurora's Board and are effective immediately. Mr. Martin has served as Chief Executiv

      9/20/24 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis Announces Results of 2024 Annual General and Special Meeting

      NASDAQ | TSX: ACB EDMONTON, AB, Aug. 12, 2024 /PRNewswire/ -  Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held Friday August 9, 2024 by virtual webcast. The total number of shares represented by shareholders present in person (virtually) and by proxy at the Meeting was 14,855,306, representing 27.23% of Aurora's issued and outstanding common shares as of the record date. All of

      8/12/24 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care